CorMedix Inc. · NASDAQ:CRMD

CorMedix — Investor Presentation (November 2022)

17 slides from CorMedix's investor presentation, November 2022

  1. Slide 1: Corporate Presentation

    Slide 1: Corporate Presentation

    Corporate Presentation November 2022

  2. Slide 2: Forward-Looking Statements

    Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management’s expectations, bel

  3. Slide 3: CorMedix is an Attractive Investment Opportunity, with Lead Product DefenCath

    Slide 3: CorMedix is an Attractive Investment Opportunity, with Lead Product DefenCath

    CorMedix is an Attractive Investment Opportunity, with Our Lead Product DefenCathTM Targeting Substantial Market Opportunities DefenCath is intended initially for CVCs used by hemodialysis patients with kidney failure to reduce the risk and incidence of catheter related blood stream infections (CRBS

  4. Slide 4: CorMedix Executive Leadership Team

    Slide 4: CorMedix Executive Leadership Team

    CorMedix Executive Leadership Team JO I NED CO RMEDI X PRI O R EXPERI ENCE • Chief Commercial Officer of Amneal Specialty Joe Todisco 2022 • Co-founder and Chief Executive of Gemini Laboratories Chief Executive Officer • Commercial Strategy and business development at Ranbaxy • Head of Strategy at O

  5. Slide 5: Developing DefenCath: Multiple Potential Therapeutics Areas

    Slide 5: Developing DefenCath: Multiple Potential Therapeutics Areas

    Developing DefenCath: Multiple Potential Therapeutics Areas • No pharmacologic agents approved in the U.S. for the prevention or reduction of CRBSI in central venous catheters • DefenCath is an antimicrobial catheter lock solution designed to reduce CRBSIs and clotting • Broad antimicrobial activity

  6. Slide 6: Catheter Related Bloodstream Infections (CRBSI) are a Common and Life-threatening Complication of CVC use

    Slide 6: Catheter Related Bloodstream Infections (CRBSI) are a Common and Life-threatening Complication of CVC use

    Catheter Related Bloodstream Infections (CRBSI) are a Common and Life-threatening Complication of CVC use Disease Burden Health Economics ~80% of patients starting HD will have a CVC inserted for HD patients with CRBSIs have almost 2x more vascular access 1 hospitalizations per year 4 CRBSIs can occ

  7. Slide 7: Phase 3 LOCK-IT-100 – Compelling Clinical Profile

    Slide 7: Phase 3 LOCK-IT-100 – Compelling Clinical Profile

    Phase 3 LOCK-IT-100 – Compelling Clinical Profile 3 Objective to demonstrate the efficacy and safety of Interim Analysis Full Study DefenCath as a catheter lock solution for the prevention of Total CRBSIs (D / H) 28 (6 D / 22 H) 41 (9 D / 32 H) CRBSI and the incidence of treatment-emergent adverse e

  8. Slide 8: Large Addressable Market Opportunity in Hemodialysis

    Slide 8: Large Addressable Market Opportunity in Hemodialysis

    Large Addressable Market Opportunity in Hemodialysis (Inpatient + Outpatient) Setting Of Care Addressable Market Reimbursement Dynamics NTAP (New Technology Add-On Payment) is an additional payment for drugs that 3mm-5mm* lumen locks per year, exceed a DRG payment amount by at least one standard dev

  9. Slide 9: Key Takeaways from Inpatient HECON Analysis

    Slide 9: Key Takeaways from Inpatient HECON Analysis

    Key Takeaways from Inpatient HECON Analysis CorMedix performed a retrospective database analysis of the largest hospital discharge database in the US, to assess the proportion of 381,336 HD-CVC patients between 2017-2021 with a diagnosis of AKI, CKD or ESRD among hospitalized inpatients, and to exam

  10. Slide 10: NTAP, TDAPA & Separate Reimbursement

    Slide 10: NTAP, TDAPA & Separate Reimbursement

    NTAP, TDAPA & Separate Reimbursement HOSPITAL INPATIENT SEPARATELY NTAP 9 New Technology Add-on Payment REIMBURSABLE Unique J Code (HCPCS Code) DefenCath application for NTAP has been reviewed favorably by CMS What is it? Additional payment for drugs that exceed a DRG payment amount by at least one

  11. Slide 11: Commercial Execution Focus

    Slide 11: Commercial Execution Focus

    Commercial Execution Focus Hospital (Inpatient) Dialysis Facility (Outpatient) A commercial organization of ~30 can provide A highly focused internal team of ~12 can provide adequate coverage for launch adequate coverage for launch: ~6,100 hospitals in the US, per AHA statistics There are ~7,600 dia

  12. Slide 12: DefenCath Regulatory Status & Timeline

    Slide 12: DefenCath Regulatory Status & Timeline

    DefenCath Regulatory Status & Timeline • DefenCath granted Fast Track designation by FDA recognizing potential to address unmet medical need, as well as QIDP (Qualified Infectious Disease Product), which provides an additional 5 years of market exclusivity • DefenCath NDA granted rolling submission

  13. Slide 13: DefenCath Regulatory Status & Timeline, cont.

    Slide 13: DefenCath Regulatory Status & Timeline, cont.

    DefenCath Regulatory Status & Timeline, cont. • CorMedix resubmitted the DefenCath NDA in February 2022, was accepted as a complete Class 2 response with a six-month review cycle and given a PDUFA Goal Date in Q3 2022 • FDA advised our CMO it would conduct a pre-approval inspection in mid-summer 202

  14. Slide 14: DefenCath Manufacturing & Supply Chain Strategy

    Slide 14: DefenCath Manufacturing & Supply Chain Strategy

    DefenCath Manufacturing & Supply Chain Strategy • CorMedix is pursuing a three-prong strategy to solidify our supply chain and mitigate the risk of any long-term compliance disruptions at our existing CMO or existing API supplier: • Pathway 1 – Existing CMO + Existing API Supplier – The fastest path

  15. Slide 15: Financial Highlights

    Slide 15: Financial Highlights

    Financial Highlights Key Statistics Balance Sheet Exchange NASDAQ Global Market Cash and short-term investments* $59.0 million** Common Stock 41.3 million shares as of 11/10/2022 Debt None Market cap ~$150 million * Excluding restricted cash ** as of 9/30/2022 CONFIDENTIAL AND NOT FOR DISTRIBUTION W

  16. Slide 16: CorMedix Key Investment Highlights

    Slide 16: CorMedix Key Investment Highlights

    CorMedix Key Investment Highlights DefenCath is a novel product • ~80% of patients starting HD will have a CVC inserted for vascular access addressing a significant unmet • $2.3 billion spent annually on CRBSI medical need Compelling Efficacy and • 71% reduction in risk of CRBSI Safety Profile • Hig

  17. Slide 17: References

    Slide 17: References

    References 1. USRDS End Stage Renal Disease 2020 Annual Data Report; Chapter 3; Vascular Access 2. Araya S. et.al.; Racial and Sex Disparities in Catheter Use and Dialysis Access in the United States Medicare Population JASN 31: 625–636, 2020 3. LOCK-IT-100: CRMD003, A Novel Tauroline-Based Catheter

Source: Internet Archive copy of cormedix.com

More decks from CorMedix Inc.

All 34 CorMedix decks